{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:15:30Z","timestamp":1789683330692,"version":"4.0.1"},"reference-count":94,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Evidence-based Traditional Chinese Medicine","award":["zyyzdxk-2023249"],"award-info":[{"award-number":["zyyzdxk-2023249"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec040\">\n<jats:title>Background<\/jats:title>\n<jats:p>Currently, quadruple therapy is unanimously recommended as the current first-line treatment option for Helicobacter pylori (H. Pylori) eradication. However, the drug composition of quadruple therapy is very complex, and the efficacy and safety between them is not clear.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec041\">\n<jats:title>Aims<\/jats:title>\n<jats:p>To compare the efficacy and safety of H. Pylori eradication regimens, which were recommended by the Fifth Consensus of China, by network meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec042\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Literature databases were used to retrieve clinical randomized controlled trials of H. Pylori eradication. Network meta-analysis was performed using BUGSnet and meta package of R software, using OR values as effect size, and SUCRA was used to rank the efficacy of interventions under each outcome.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec043\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 55 studies and 130 arms were included. The NMA analysis found that the top regimen in term of eradication rate outcome was: Rabeprazole +\u2009 Bismuth +\u2009 Furazolidone +\u2009 Tetracycline (SUCRA, 97.5). In terms of safety outcomes: Lansoprazole +\u2009 Bismuth +\u2009 Amoxycillin +\u2009 Clarithromycin (SUCRA, 91.97).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec044\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The bismuth quadruple therapies recommended by the guidelines for the treatment of H. Pylori have good performance in terms of four-week eradication rate and safety outcome indicators, and due to the different resistance of antibiotics in different regional populations, rational use of drugs should be combined with local conditions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0318937","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:35:53Z","timestamp":1740076553000},"page":"e0318937","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-1416","authenticated-orcid":true,"given":"Jiali","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-3891","authenticated-orcid":true,"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"27","key":"pone.0318937.ref001","first-page":"8979","article-title":"Helicobacter pylori: friend or foe?","volume":"20","author":"SD Malnick","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"pone.0318937.ref002","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"JKY Hooi","year":"2017","journal-title":"Gastroenterology"},{"issue":"05","key":"pone.0318937.ref003","first-page":"265","article-title":"Epidemiological survey of Helicobacter pylori infection in a natural population in China","volume":"15","author":"WD Zhang","year":"2010","journal-title":"Modern Dig Interv Med"},{"issue":"7","key":"pone.0318937.ref004","article-title":"The Fifth National Consensus Report on the treatment of Helicobacter pylori Infection","author":"WZ Liu","year":"2017","journal-title":"Chin J Intern Med"},{"issue":"16","key":"pone.0318937.ref005","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3390\/jcm10163473","article-title":"Clinical relevance of helicobacter pylori infection","volume":"10","author":"I Mladenova","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"pone.0318937.ref006","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrgastro.2017.57","article-title":"Helicobacter pylori infection and antibiotic resistance: a WHO high priority?","volume":"14","author":"BN Dang","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"pone.0318937.ref007","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/diagnostics12020508","article-title":"Evolution of diagnostic methods for helicobacter pylori infections: from traditional tests to high technology, Adv Sens Discrim Tools","volume":"12","author":"AI Cardos","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"pone.0318937.ref008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of helicobacter pylori infection-the maastricht V\/Florence consensus report","volume":"66","author":"European Helicobacter and Microbiota Study Group and Consensus panel","year":"2017","journal-title":"Gut"},{"issue":"19","key":"pone.0318937.ref009","first-page":"1","article-title":"Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysis","volume":"13","author":"D Ling","year":"2013","journal-title":"Ont Health Technol Assess Ser"},{"issue":"9","key":"pone.0318937.ref010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"faculty members of Kyoto Global Consensus Conference","year":"2015","journal-title":"Gut"},{"issue":"1","key":"pone.0318937.ref011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"CA Fallone","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0318937.ref012","first-page":"212","article-title":"ACG clinical guideline: treatment of helicobacter pylori infection [published correction appears in Am J Gastroenterol. 2018 Jul;113(7):1102]","volume":"112","author":"WD Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"pone.0318937.ref013","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of helicobacter pylori infection","volume":"119","author":"WD Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"pone.0318937.ref014","doi-asserted-by":"crossref","first-page":"759249","DOI":"10.3389\/fphar.2021.759249","article-title":"Influence of Cytochrome P450 2C19 genotype on helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis","volume":"12","author":"Y Morino","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"pone.0318937.ref015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14787210.2018.1511427","article-title":"Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies","volume":"16","author":"DY Graham","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pone.0318937.ref016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/antibiotics11010078","article-title":"Empiric \u201cthree-in-one\u201d bismuth quadruple therapy for second-line helicobacter pylori eradication: an intervention study in Southern Italy","volume":"11","author":"G Losurdo","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"pone.0318937.ref017","doi-asserted-by":"crossref","first-page":"e12565","DOI":"10.1111\/hel.12565","article-title":"Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis","volume":"24","author":"SW Ko","year":"2019","journal-title":"Helicobacter"},{"issue":"05","key":"pone.0318937.ref018","first-page":"266","article-title":"Reticulated meta-analysis priority reporting entries: interpretation of PRISMA extended statement","volume":"32","author":"JH Tian","year":"2015","journal-title":"China Drug Evaluation"},{"issue":"10","key":"pone.0318937.ref019","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jclinepi.2008.10.013","article-title":"Indirect comparison: relative risk, fall- cies, and odds solution","volume":"62","author":"S Eckermann","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"pone.0318937.ref020","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-analysis with R","author":"G Schwarzer","year":"2015"},{"issue":"4","key":"pone.0318937.ref021","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graph package","volume":"15","author":"A Chaimani","year":"2015","journal-title":"The Stata Journal: Promoting communications on statistics and Stata"},{"issue":"4","key":"pone.0318937.ref022","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"A Nikolakopoulou","year":"Apr","journal-title":"PLoS Med"},{"issue":"5","key":"pone.0318937.ref023","first-page":"6","article-title":"Network Meta-analysis Using R Netmeta Package","volume":"14","author":"C Zhang","year":"2014","journal-title":"Chin J Evid Med"},{"issue":"28","key":"pone.0318937.ref024","first-page":"6","article-title":"Discussion on a new method of quadruple eradication of Helicobacter pylori","volume":"14","author":"C Bai","year":"2019","journal-title":"Chin J Pract Med"},{"issue":"06","key":"pone.0318937.ref025","first-page":"596","article-title":"Effect of doxycycline and amoxicillin in the eradication of Helicobacter pylori","volume":"40","author":"JE Chen","year":"2018","journal-title":"Zhejiang Med J"},{"issue":"12","key":"pone.0318937.ref026","first-page":"716","article-title":"Effect of Lansoprazole tetrad therapy on patients with Helicobacter pylori positive gastric ulcer and the influence of IFN- IL-2, IL-12 and other inflammatory factors","volume":"26","author":"JX Chen","year":"2018","journal-title":"World Chin Dig"},{"key":"pone.0318937.ref027","article-title":"Observation on the efficacy of four-line regimen containing furazolidone in the initial treatment of Helicobacter pylori","author":"W Chen","year":"2012"},{"issue":"03","key":"pone.0318937.ref028","first-page":"24","article-title":"Therapeutic effect of levofloxacin on Helicobacter pylori","volume":"6","author":"XY Chen","year":"2009","journal-title":"J Yangtze Univ Med"},{"issue":"4","key":"pone.0318937.ref029","first-page":"50","article-title":"Efficacy of three kinds of quadruple therapy against Helicobacter pylori in peptic ulcer","author":"XH Cheng","year":"2014","journal-title":"China Clin Pract Med"},{"issue":"Z2","key":"pone.0318937.ref030","first-page":"153","article-title":"Effect of esomeprazole quadruplex therapy on eradication of Helicobacter pylori","volume":"2","author":"YC Deng","year":"2017","journal-title":"Big Doct"},{"issue":"02","key":"pone.0318937.ref031","first-page":"327","article-title":"Effect of esomeprazole based quadruple therapy on eradication of Helicobacter pylori and treatment of peptic ulcer","volume":"28","author":"B Tong","year":"2015","journal-title":"Heilongjiang Med"},{"issue":"4","key":"pone.0318937.ref032","first-page":"544","article-title":"Analysis of therapeutic effect of quadruple therapy on Helicobacter pylori in patients with gastric ulcer","volume":"35","author":"W Dong","year":"2013","journal-title":"Hebei Med"},{"issue":"10","key":"pone.0318937.ref033","first-page":"26","article-title":"Comparison of efficacy of quadruple therapy of rabeprazole and omeprazole in the treatment of peptic ulcer associated with Helicobacter pylori","volume":"16","author":"M Feng","year":"2019","journal-title":"North Pharm"},{"issue":"1","key":"pone.0318937.ref034","first-page":"23","article-title":"Clinical analysis of quadruple therapy containing furazolidone and clarithromycin for eradication of Helicobacter pylori","volume":"7","author":"MC He","year":"2022","journal-title":"J Syst Med"},{"issue":"7","key":"pone.0318937.ref035","first-page":"120","article-title":"Efficacy and safety of quadruple therapy of rabeprazole and omeprazole in patients with Helicobacter pylori positive peptic ulcer","volume":"34","author":"XJ He","year":"2011","journal-title":"Med Equipm"},{"issue":"1","key":"pone.0318937.ref036","first-page":"5","article-title":"Effect of quadruple therapy containing doxycycline and furazolidone on initial treatment failure of Hp infection","volume":"19","author":"LL Hong","year":"2017","journal-title":"Pract Clin Med"},{"issue":"15","key":"pone.0318937.ref037","first-page":"13","article-title":"Efficacy observation and cost-effectiveness analysis of three proton pump inhibitors to eradicate Helicobacter pylori in the treatment of peptic ulcer","volume":"9","author":"ZL Huang","year":"2016","journal-title":"J Clin Drug Use"},{"issue":"27","key":"pone.0318937.ref038","first-page":"80","article-title":"Effect of quadruple therapy containing furazolidone on eradication of Helicobacter pylori","author":"HB Ji","year":"2018","journal-title":"Health Compul Read"},{"key":"pone.0318937.ref039","volume-title":"Study on drug resistance of Helicobacter pylori and eradication effect of bismuth quadruple regimen","author":"CC Kong","year":"2014"},{"issue":"1","key":"pone.0318937.ref040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13099-020-00378-1","article-title":"Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study","volume":"12","author":"SY Kong","year":"2020","journal-title":"Gut Pathog"},{"issue":"11","key":"pone.0318937.ref041","first-page":"632","article-title":"Clinical application effect of Bifidobacterium triple live capsule combined with different quadruple therapy on eradication of Helicobacter pylori","volume":"7","author":"CJ Li","year":"2019","journal-title":"Chin J Dis Relief Med"},{"issue":"26","key":"pone.0318937.ref042","first-page":"4279","article-title":"Clinical effect of quadruple therapy with doxycycline and furazolidone on initial treatment of Helicobacter pylori infection","author":"S Li","year":"2015","journal-title":"Intern J Chin Dig"},{"issue":"06","key":"pone.0318937.ref043","first-page":"542","article-title":"Clinical efficacy of doxycycline-containing and furazolidone-containing regimens in the remedial treatment of Helicobacter pylori","volume":"38","author":"S Li","year":"2019","journal-title":"J Anhui South Med College"},{"issue":"98","key":"pone.0318937.ref044","first-page":"17","article-title":"Clinical study of Esomeprazole quadruplex therapy in the treatment of pylori positive peptic ulcer","volume":"15","author":"XT Li","year":"2015","journal-title":"World Latest Med Inf Abstr"},{"issue":"03","key":"pone.0318937.ref045","first-page":"193","article-title":"Comparison of two types of quadruple therapy in the treatment of Helicobacter pylori infection","volume":"28","author":"XY Li","year":"2016","journal-title":"J Henan Med College"},{"issue":"35","key":"pone.0318937.ref046","first-page":"42","article-title":"Clinical effect of Levofloxacin lactate tablet in the treatment of gastric ulcer complicated with Hp infection and its influence on levels of inflammatory factors","volume":"5","author":"C Liang","year":"2020","journal-title":"Clin Med Res Pract"},{"issue":"07","key":"pone.0318937.ref047","first-page":"1112","article-title":"Effect analysis of four kinds of Helicobacter pylori infection eradication treatment regimen","volume":"14","author":"SZ Liu","year":"2012","journal-title":"Chin Med Guide"},{"issue":"21","key":"pone.0318937.ref048","first-page":"1559","article-title":"Pharmacoeconomic evaluation of quadruple proton pump inhibitor therapy in the treatment of Helicobacter pylori positive duodenal bulbar ulcer","author":"YQ Liu","year":"2017","journal-title":"Jiangsu Med"},{"issue":"02","key":"pone.0318937.ref049","first-page":"14","article-title":"Comparative study on the eradication of Helicobacter pylori by quadruple therapy with Esomeprazole, Rabeprazole and Pantoprazole","volume":"39","author":"X Lv","year":"2018","journal-title":"J Med Forum"},{"issue":"55","key":"pone.0318937.ref050","first-page":"21","article-title":"Analysis of the clinical effect of anti-helicobacter pylori in the treatment of peptic ulcer","volume":"16","author":"HG Ma","year":"2016","journal-title":"World Latest Med Inf Abstr"},{"issue":"26","key":"pone.0318937.ref051","first-page":"40","article-title":"Retrospective analysis of eradication of Helicobacter pylori for treatment of 60 cases","volume":"31","author":"YG Qiao","year":"2015","journal-title":"Chin Community Phys"},{"issue":"13","key":"pone.0318937.ref052","first-page":"42","article-title":"Clinical efficacy and safety evaluation of esomeprazole based quadruple therapy in the treatment of Helicobacter pylori positive peptic ulcer","author":"J Ren","year":"2020","journal-title":"Women\u2019s Health Res"},{"issue":"4","key":"pone.0318937.ref053","first-page":"390","article-title":"Quad solution containing different antibiotics the curative effect of helicobacter pylori eradication comparison","volume":"20","author":"XH Shen","year":"2017","journal-title":"J Pract Med Clin"},{"issue":"9","key":"pone.0318937.ref054","first-page":"21","article-title":"Effect of rabeprazole sodium on patients with Helicobacter pylori positive duodenal ulcer","author":"J Shi","year":"2018","journal-title":"Chin Foreign Med Res"},{"issue":"11","key":"pone.0318937.ref055","first-page":"1266","article-title":"Effect of bismuth-containing quadruple therapy as a remedial treatment after Helicobacter pylori eradication failure","volume":"33","author":"JS Wang","year":"2013","journal-title":"Jiangsu Med"},{"issue":"09","key":"pone.0318937.ref056","first-page":"1744","article-title":"Observation on the efficacy of two remedial schemes after the first eradication failure of Helicobacter pylori","volume":"20","author":"JX Wang","year":"2016","journal-title":"Anhui Med"},{"issue":"02","key":"pone.0318937.ref057","first-page":"29","article-title":"Clinical effect of quadruple regimen containing furazolidone on duodenal ulcer with positive Helicobacter pylori","volume":"2","author":"WH Wang","year":"2017","journal-title":"Clin Med Res Pract"},{"issue":"19","key":"pone.0318937.ref058","first-page":"88","article-title":"Curative effect of domestic rabeprazole based quadruple therapy in the treatment of Helicobacter pylori infection","author":"X Wu","year":"2020","journal-title":"Health Compuls Read"},{"issue":"17","key":"pone.0318937.ref059","first-page":"125","article-title":"Efficacy and pharmacoeconomic evaluation of rabeprazole, omeprazole and Pantoprazole in the treatment of peptic ulcer caused by Helicobacter pylori infection","volume":"28","author":"Y Xiong","year":"2022","journal-title":"Mod Med"},{"issue":"07","key":"pone.0318937.ref060","first-page":"112","article-title":"Evaluation of clinical implementation effect of four kinds of Helicobacter pylori eradication programs","volume":"33","author":"Q Yang","year":"2017","journal-title":"Gansu Sci Technol"},{"issue":"10","key":"pone.0318937.ref061","first-page":"1073","article-title":"Containing the quadruple of amoxicillin and bismuth agent solution curative effect observation of helicobacter pylori eradication","volume":"40","author":"QZ Yang","year":"2015","journal-title":"J Guiyang Med College"},{"issue":"8","key":"pone.0318937.ref062","first-page":"159","article-title":"Efficacy of omeprazole in the treatment of gastric ulcer","volume":"13","author":"WD Yang","year":"2021","journal-title":"Chin J Continu Med Educ"},{"issue":"05","key":"pone.0318937.ref063","first-page":"424","article-title":"Comparative study on the curative effect of different four-combination remedies on the eradication of Helicobacter pylori","volume":"35","author":"X Yang","year":"2015","journal-title":"ChinJ Pract Intern Med"},{"issue":"05","key":"pone.0318937.ref064","first-page":"153","article-title":"Therapeutic effect of Esomeprazole and furazolidone on Helicobacter pylori","volume":"8","author":"YR Yao","year":"2011","journal-title":"China Med Review"},{"issue":"6","key":"pone.0318937.ref065","first-page":"14","article-title":"Different quad scheme for treatment of helicobacter pylori associated gastric ulcer","volume":"5","author":"H Zeng","year":"2020","journal-title":"J Clin Med Res Pract"},{"issue":"5","key":"pone.0318937.ref066","first-page":"54","article-title":"Effect of levofloxacin combined with amoxicillin in the eradication of chronic gastritis infected by Helicobacter pylori","volume":"29","author":"HZ Zhai","year":"2016","journal-title":"Chin Med"},{"issue":"z1","key":"pone.0318937.ref067","first-page":"59","article-title":"Comparison of clinical efficacy of different proton pump inhibitor quadruple therapy in the treatment of Helicobacter pylori HP-associated peptic ulcer","volume":"15","author":"SB Zhan","year":"2020","journal-title":"Chin J Em Resusc Med"},{"issue":"16","key":"pone.0318937.ref068","first-page":"176","article-title":"With levofloxacin quadruple therapy efficacy analysis of eradicating helicobacter pylori infection","volume":"8","author":"HB Zhang","year":"2013","journal-title":"J Pract Med"},{"issue":"6","key":"pone.0318937.ref069","first-page":"380","article-title":"Clinical effect of rabeprazole quadruplex therapy on peptic ulcer","volume":"28","author":"HW Zhang","year":"2013","journal-title":"J Occup Health Injury"},{"key":"pone.0318937.ref070","volume-title":"Selection of Helicobacter pylori infection eradication program and analysis of related factors in Suzhou area","author":"MX Zhang","year":"2014"},{"issue":"78","key":"pone.0318937.ref071","first-page":"3","article-title":"Comparative study of different regimens in the treatment of Helicobacter pylori infection in Tibetan population in southern Gannan","volume":"17","author":"WQ Zhang","year":"2017","journal-title":"World Latest Med Inf Abstr"},{"issue":"10","key":"pone.0318937.ref072","first-page":"885","article-title":"Efficacy and safety of rabeprazole and Esomeprazole sodium in the treatment of Helicobacter pylori infection","volume":"9","author":"XH Zhang","year":"2021","journal-title":"Chin J Pract Int Med"},{"issue":"6","key":"pone.0318937.ref073","first-page":"698","article-title":"Study on the efficacy and safety of different quadruple regimens containing bismuth in initial treatment of Helicobacter pylori","volume":"5","author":"XX Zhang","year":"2022","journal-title":"J West China Phar"},{"issue":"22","key":"pone.0318937.ref074","first-page":"3116","article-title":"Comparative effect of four bismuth-containing quadruple regimens on eradication of Helicobacter pylori","volume":"29","author":"Y Zhang","year":"2018","journal-title":"Hainan Med"},{"issue":"34","key":"pone.0318937.ref075","first-page":"75","article-title":"Comparison of efficacy and adverse reactions of omeprazole and esomeprazole in the treatment of Helicobacter pylori positive gastric ulcer","volume":"20","author":"YF Zhang","year":"2022","journal-title":"Chin Med Guid"},{"issue":"15","key":"pone.0318937.ref076","first-page":"172","article-title":"Comparison of efficacy of rabeprazole and omeprazole in the treatment of Helicobacter pylori peptic ulcer","author":"ZH Zheng","year":"2021","journal-title":"Health Friend"},{"issue":"4","key":"pone.0318937.ref077","first-page":"60","article-title":"Effects of Rabeprazole quadruple therapy on COX-2 and E-cadherin in patients with Helicobacter pylori positive chronic gastritis","volume":"6","author":"X Zhou","year":"2019","journal-title":"J Clin Med Res Pract"},{"issue":"3","key":"pone.0318937.ref078","first-page":"146","article-title":"Comparison of two proton pump inhibitors in the treatment of Helicobacter pylori positive duodenal ulcer","author":"J Zou","year":"2014","journal-title":"Mod Med"},{"issue":"4","key":"pone.0318937.ref079","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"I Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0318937.ref080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4161\/gmic.25930","article-title":"Current recommendations for Helicobacter pylori therapy in a world of evolving resistance","volume":"4","author":"F M\u00e9graud","year":"2013","journal-title":"Gut Microbes"},{"issue":"3","key":"pone.0318937.ref081","doi-asserted-by":"crossref","first-page":"e12889","DOI":"10.1111\/hel.12889","article-title":"Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study","volume":"27","author":"Z Song","year":"2022","journal-title":"Helicobacter"},{"issue":"6","key":"pone.0318937.ref082","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/jac\/dkz046","article-title":"A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial","volume":"74","author":"WC Tai","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"pone.0318937.ref083","doi-asserted-by":"crossref","first-page":"17562848211064080","DOI":"10.1177\/17562848211064080","article-title":"Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship","volume":"14","author":"A Shiotani","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"pone.0318937.ref084","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","article-title":"Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea","volume":"15","author":"BH Lee","year":"2010","journal-title":"Helicobacter"},{"issue":"1","key":"pone.0318937.ref085","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00004836-199506001-00007","article-title":"Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies","volume":"20","author":"H Lamouliatte","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"pone.0318937.ref086","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MEG.0b013e3283337146","article-title":"A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial","volume":"22","author":"J Ma","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0318937.ref087","first-page":"163960","article-title":"Comparison of second-line quadruple therapies with or without bismuth for helicobacter pylori infection","author":"GH Jheng","year":"2015","journal-title":"Biomed Res Int"},{"key":"pone.0318937.ref088","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.2147\/DDDT.S136240","article-title":"Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection","volume":"11","author":"MT Mascellino","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"pone.0318937.ref089","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.1097\/MD.0000000000014408","article-title":"Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study","volume":"98","author":"DM Yi","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"pone.0318937.ref090","first-page":"448","article-title":"High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study","volume":"28","author":"A Zullo","year":"2015","journal-title":"Ann Gastroenterol"},{"issue":"10","key":"pone.0318937.ref091","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41395-018-0217-2","article-title":"Systematic review with meta-analysis: concomitant therapy vs. triple therapy for the first-line treatment of helicobacter pylori infection","volume":"113","author":"Taiwan Gastrointestinal Disease Helicobacter Consortium","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"pone.0318937.ref092","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MEG.0000000000001835","article-title":"Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis","volume":"33","author":"H Xu","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0318937.ref093","article-title":"Efficacy and safety of first-line treatment regimen for Helicobacter pylori: a systematic review and network meta-analysis","author":"QY WU","year":"2017"},{"issue":"9","key":"pone.0318937.ref094","first-page":"1068","article-title":"Chinese national clinical practice guideline on Helicobacter pylori eradication treatment [published correction appears in","volume":"137","author":"L Zhou","year":"20222024","journal-title":"Chin Med J (Engl)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:36:18Z","timestamp":1740076578000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318937"}},"subtitle":[],"editor":[{"given":"Addisu","family":"Melese Dagnaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0318937","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}